Company profile: Fortress Biotech
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies, focused on acquiring, developing and commercializing therapeutic products. Pipeline: Cosibelimab (fully human PD-L1 antibody) for EGFR mutationβpositive non-small cell lung cancer; DFD-29 for inflammatory lesions of rosacea; IV Tramadol for post-surgical pain; AJ201 for spinal and bulbar muscular atrophy; BAER-101 for CNS disorders.
Products and services
- AJ201: A multi-mechanism therapy engineered for spinal and bulbar muscular atrophy, aiming to modify disease by promoting degradation of the abnormal androgen receptor (AR) protein
- BAER-101: A Ξ±2/3βsubtype-selective GABA A positive allosteric modulator in development for central nervous system disorders, with selectivity limited to Ξ±2/3 subunits
- Cosibelimab: A fully-human monoclonal antibody targeting PD-L1, engineered to treat epidermal growth factor receptor mutationβpositive nonβsmall cell lung cancer patients
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Fortress Biotech
Cyclenium Pharma
HQ: Canada
Website
- Description: Provider of next-generation macrocyclic drug discovery technology (CMRT) and the QUEST library of small-molecule macrocycles to identify novel therapeutics for difficult disease targets. Offers collaborative drug discovery, out-licensing of advanced leads (e.g., anti-flaviviral agents, opioid receptor agonists), and in-licensing opportunities in oncology and anti-infectives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Cyclenium Pharma company profile β
Precigen
HQ: United States
Website
- Description: Provider of bio-therapeutic control systems and platforms to minimize toxicity, including UltraCAR-T, a non-viral multigenic CAR-T cell therapy enabling rapid manufacturing with enhanced in vivo persistence and tumor response; ActoBiotics, microbe-based agents delivering disease-modifying treatments locally; and Exemplar Genetics gene-edited minipig models and preclinical services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Precigen company profile β
Tolmar
HQ: United States
Website
- Description: Provider of pharmaceutical research, development, manufacturing and commercial operations, delivering proprietary and generic products in dermatology, oncology, and dental therapeutics, including ELIGARD (leuprolide acetate for prostate cancer), Fensolvi (leuprolide acetate for central precocious puberty), and topical dermatology genericsβointments, creams, gels, and lotions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Tolmar company profile β
Verseon
HQ: United States
Website
- Description: Provider of an AI- and quantum physicsβbased drug discovery platform that explores billions of chemical options to identify novel leads; clinical candidate development advancing multiple synthesized and characterized candidates with unique therapeutic profiles; and AI-enabled patient recruitment and trial conduct using a proprietary network for more efficient studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Verseon company profile β
Altor BioScience
HQ: United States
Website
- Description: Provider of immunotherapeutic agents for cancer, viral infections, and autoimmune diseases, including ANKTIVA (Nβ803), an ILβ15 receptor agonist for nonβmuscle invasive bladder cancer; investigational cancer and viral therapies and vaccines (personalized neoepitope-based, HIV, HPV); TriβAd5 vaccine for Lynch syndrome; STAR Fusion reagents for diagnosis/targeting, STAR Multimer reagents for research; and clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Altor BioScience company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Fortress Biotech
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Fortress Biotech
2.2 - Growth funds investing in similar companies to Fortress Biotech
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Fortress Biotech
4.2 - Public trading comparable groups for Fortress Biotech
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β